The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.
Tamara K MoyoJason H MendlerRaphael ItzyksonAshwin KishtagariEric SolaryAdam C SeegmillerAaron T GerdsGregory D AyersAmy E DezernAziz NazhaPeter ValentArjan A van de LoosdrechtFrancesco OnidaLisa PleyerBlanca Xicoy CiriciRaoul TibesKlaus GeisslerRami S KomrokjiJing ZhangUlrich GermingDavid P SteensmaDaniel H WisemanMichael PfeilstöeckerChiara ElenaNicholas C P CrossJean-Jacques KiladjianMichael LuebbertRuben A MesaGuillermo Montalban-BravoGuillermo F SanzUwe PlatzbeckerMrinal M PatnaikEric PadronValeria SantiniPierre FenauxMichael R Savonanull nullPublished in: BMC cancer (2022)
This trial was registered with ClinicalTrials.gov on August 19, 2019 (Registration No. NCT04061421).